Energy Transfer and Altria both yield more than 6%, but their payouts come from very different cash-flow engines.
Energy Transfer increased its second-quarter distribution to $0.34 per unit, or $1.36 annualized. The partnership called it the nineteenth consecutive quarterly increase. Its adjusted EBITDA rose 31% from a year earlier to $5.07 billion, prompting management to raise 2026 guidance to $18.8 billion to $19.1 billion.
That growth gives Energy Transfer more payout coverage. The source calculated that its 2025 distributable cash flow covered the distribution about 1.8 times. Altria paid about 78% of trailing free cash flow as dividends. Both figures indicate current coverage, but they are not directly identical accounting measures.
Energy Transfer also carries more financial and execution risk. Its leverage has remained near the upper end of management's target range, and the partnership plans billions of dollars of annual growth investment. Large projects can support future cash flow, but delays, cost overruns or weaker commodity activity can pressure the balance sheet before new assets contribute.
Altria has the stronger balance sheet and the longer record of annual dividend increases. It raised its quarterly dividend to $1.11 in August and expects 2026 adjusted EPS of $5.61 to $5.72. Yet its core U.S. cigarette volumes continue to decline, so pricing, buybacks and new nicotine products must offset a shrinking base.
The tax structure is another meaningful difference. Energy Transfer is a master limited partnership, and investors generally receive a Schedule K-1 rather than the simpler dividend reporting associated with Altria shares. Account type and tax circumstances can therefore change the practical value of the headline yield.
On current operating evidence, Energy Transfer offers the stronger growth and coverage profile. Altria offers simpler ownership, lower leverage and a steadier payout history. The key risk for Energy Transfer is whether its capital program pushes leverage above target; the key risk for Altria is whether cigarette-volume decline accelerates faster than pricing and reduced-risk products can compensate.